Evidence map›Paper›PMID 39978817›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

IL13Rα2-Targeting Antibodies for Immuno-PET in Solid Malignancies.

Leah Gajecki, Irina V Lebedeva, Yu-Rou Liao, Daisy Ambriz, Lukas M Carter, Melina Kumpf, Samantha Lovibond, Justin S Hachey, Maya S Graham, Michael Postow and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Leah GajeckiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Irina V LebedevaSanders Tri-Institutional Therapeutics Discovery Institute, New York, New York.
Yu-Rou LiaoSanders Tri-Institutional Therapeutics Discovery Institute, New York, New York.
Daisy AmbrizSanders Tri-Institutional Therapeutics Discovery Institute, New York, New York.
Lukas M CarterDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Melina KumpfDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Samantha LovibondDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Justin S HacheyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Maya S GrahamDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael PostowDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
David P AndrewSanders Tri-Institutional Therapeutics Discovery Institute, New York, New York.
Manuel BacaSanders Tri-Institutional Therapeutics Discovery Institute, New York, New York.
Heiko SchöderDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Darren R VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Simone KrebsDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; sskrebs@mdanderson.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2M
Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten captureR37CA262557 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Simone Krebs · 2021 to 2026
$3.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA232130NCI NIH HHS R37 CA262557
6 · The paper itself

Abstract

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor frequently expressed in solid malignancies, such as glioblastoma and melanoma, with limited expression in healthy tissue, rendering it an ideal target for noninvasive and specific tumor delineation. In this study, we report the development of 5 novel IL13Rα2-targeted human monoclonal antibodies (mAbs) KLG-1-5; in subsequent in vitro and in vivo studies after radiolabeling with

Indexed as

Antibodies, MonoclonalInterleukin-13 Receptor alpha2 SubunitNeoplasmsPositron-Emission TomographyAnimalsCell Line, TumorGlioblastomaHumansMiceRadioisotopesTissue DistributionZirconiumAntibodies, MonoclonalInterleukin-13 Receptor alpha2 SubunitRadioisotopesZirconiumZirconium-89antibodiesglioblastomaIL13Rα2immuno-PETmelanoma

Identifiers

PMID39978817
PMCPMC11960613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.